slotkoers
Taipei Exchange
00:00:00 07-06-2024
|
Variatie 5 dagen
|
Verschil t.o.v. 1 jan (%)
|
29,85
TWD
|
+1,70%
|
|
+1,36%
|
+12,01%
|
Fiscaal tijdperk: december |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Marktkapitalisatie
1 |
1.368
|
1.416
|
1.365
|
1.316
|
1.544
|
1.519
|
Bedrijfswaarde
1 |
1.177
|
1.156
|
1.041
|
1.208
|
1.216
|
1.260
|
K/w-verhouding
|
32,4
x
|
19,6
x
|
23,3
x
|
16,4
x
|
10,1
x
|
22,2
x
|
Dividendrendement
|
2,5%
|
4,02%
|
4,18%
|
4,33%
|
4,43%
|
3,75%
|
Marktkapitalisatie/omzet
|
1,41
x
|
1,38
x
|
1,39
x
|
1,26
x
|
1,35
x
|
1,43
x
|
Bedrijfswaarde/omzet
|
1,22
x
|
1,13
x
|
1,06
x
|
1,16
x
|
1,06
x
|
1,19
x
|
Bedrijfswaarde/EBITDA
|
9,96
x
|
7,09
x
|
6,83
x
|
7,38
x
|
5,55
x
|
10,7
x
|
Bedrijfswaarde/FCF
|
110
x
|
10,5
x
|
9,38
x
|
-7,64
x
|
11,5
x
|
-24,9
x
|
FCF Yield
|
0,91%
|
9,53%
|
10,7%
|
-13,1%
|
8,69%
|
-4,02%
|
Price to Book
|
1,31
x
|
1,32
x
|
1,27
x
|
1,2
x
|
1,26
x
|
1,25
x
|
Aantal aandelen (in duizenden)
|
56.983
|
56.983
|
56.983
|
56.983
|
56.983
|
56.983
|
Referentieprijs
2 |
24,00
|
24,85
|
23,95
|
23,10
|
27,10
|
26,65
|
Datum van publicatie
|
1/04/19
|
20/03/20
|
30/03/21
|
28/03/22
|
24/03/23
|
14/03/24
|
Fiscaal tijdperk: december |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Omzet
1 |
967,4
|
1.023
|
979,4
|
1.042
|
1.143
|
1.061
|
EBITDA
1 |
118,2
|
163
|
152,5
|
163,6
|
219,2
|
117,6
|
Bedrijfsresultaat (EBIT)
1 |
42,64
|
87,26
|
75,55
|
91,74
|
153,8
|
61,21
|
Operationele Marge
|
4,41%
|
8,53%
|
7,71%
|
8,81%
|
13,46%
|
5,77%
|
Resultaat voor belastingen (EBT)
1 |
60,06
|
97,26
|
81,42
|
104,8
|
162,3
|
87,33
|
Nettowinst (verlies)
1 |
42,25
|
72,45
|
59,14
|
80,75
|
154
|
68,67
|
Nettomarge
|
4,37%
|
7,08%
|
6,04%
|
7,75%
|
13,47%
|
6,47%
|
WPA
2 |
0,7400
|
1,270
|
1,030
|
1,410
|
2,689
|
1,200
|
Free Cash Flow
1 |
10,68
|
110,2
|
111,1
|
-158,1
|
105,7
|
-50,71
|
FCF-marge
|
1,1%
|
10,77%
|
11,34%
|
-15,17%
|
9,24%
|
-4,78%
|
Kasstroomconversie (ebitda)
|
9,04%
|
67,61%
|
72,84%
|
-
|
48,2%
|
-
|
Kasstroomconversie (nettowinst)
|
25,29%
|
152,11%
|
187,77%
|
-
|
68,61%
|
-
|
Dividend per aandeel
2 |
0,6000
|
1,000
|
1,000
|
1,000
|
1,200
|
1,000
|
Datum van publicatie
|
1/04/19
|
20/03/20
|
30/03/21
|
28/03/22
|
24/03/23
|
14/03/24
|
Fiscaal tijdperk: december |
2022 Q3
|
2022 Q4
|
---|
Omzet
1 |
-
|
289,3
|
EBITDA
|
-
|
-
|
Bedrijfsresultaat (EBIT)
1 |
-
|
66,84
|
Operationele Marge
|
-
|
23,1%
|
Resultaat voor belastingen (EBT)
1 |
-
|
61,44
|
Nettowinst (verlies)
1 |
47,09
|
54,39
|
Nettomarge
|
-
|
18,8%
|
WPA
2 |
0,8200
|
0,9500
|
Dividend per aandeel
|
-
|
-
|
Datum van publicatie
|
10/11/22
|
24/03/23
|
Fiscaal tijdperk: december |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Nettoschuldpositie
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Nettokaspositie
1 |
191
|
260
|
323
|
108
|
328
|
258
|
Hefboom (schuld/ebitda)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
10,7
|
110
|
111
|
-158
|
106
|
-50,7
|
ROE (netto-inkomsten/eigen vermogen)
|
4,03%
|
6,84%
|
5,51%
|
7,42%
|
15,4%
|
5,63%
|
ROA (netto-inkomsten/totale activa)
|
1,79%
|
3,61%
|
3,14%
|
3,64%
|
5,56%
|
2,15%
|
Totale activa
1 |
2.367
|
2.009
|
1.884
|
2.216
|
2.771
|
3.201
|
Nettoactief per aandeel
2 |
18,30
|
18,80
|
18,90
|
19,30
|
21,40
|
21,40
|
Cashflow per aandeel
2 |
3,970
|
4,830
|
5,890
|
4,430
|
8,010
|
6,690
|
Capex
1 |
75,4
|
36,5
|
22
|
265
|
105
|
101
|
Capex/omzet
|
7,79%
|
3,57%
|
2,25%
|
25,42%
|
9,21%
|
9,57%
|
Datum van publicatie
|
1/04/19
|
20/03/20
|
30/03/21
|
28/03/22
|
24/03/23
|
14/03/24
|
|
Vaira. 1 jan.
|
Kapi.
|
---|
| +12,01% | 52,43 mln. | | +19,64% | 43,3 mld. | | +21,25% | 22,22 mld. | | +18,92% | 15,43 mld. | | +53,19% | 12,72 mld. | | -0,05% | 6,79 mld. | | -11,11% | 6,71 mld. | | -8,87% | 5,73 mld. | | +14,68% | 5,5 mld. | | +6,91% | 4,78 mld. |
Generieke geneesmiddelen
|